CLINICAL OUTCOMES TYRX Absorbable Antibacterial Envelope
The TYRX™ Absorbable Antibacterial Envelope helps reduce cardiac implantable electronic device (CIED) infections in high-risk patients.
Strong clinical data associates the use of the TYRX Antibacterial Envelope with a significantly lower rate of cardiac implantable electronic device (CIED) infections — infections that are both costly to the healthcare system and pose a significant mortality risk to patients.
The COMMAND, C&C (Citadel & Centurion), Valley, Vanderbilt (Non-Absorbable) and UPMC Studies were performed utilizing the TYRX™ Non-Absorbable Antibacterial Envelope.
The Vanderbilt (Absorbable) Study was performed utilizing the Absorbable TYRX™ Absorbable Antibacterial Envelope.
Bloom HL et al. Pacing Clin Electrophysiol. 2011;34(2):133-142.
Mittal S et al. Heart Rhythm. 2014;11(4):595-601.
Shariff N et al. J Cardio Electrophysiol. 2015. Online publication.
Henrikson CA et al. JACC EP.2017;3(10):1158-1167.
Sohail MR et al. Arch Intern Med. 2011;171(20):1821-1828.